La FDA aprueba la primera terapia genética para tratar la distrofia muscular de Duchenne
VIERNES, 23 de junio de 2023 (HealthDay News) — El jueves, la Administración de Alimentos y Medicamentos (FDA) de EE. UU. aprobó al medicamento Elevidys, la primera terapia genética para el tratamiento de los niños con distrofia muscular de Duchenne …
Learn MoreFDA Approves First Gene Therapy to Treat Duchenne Muscular Dystrophy
FRIDAY, June 23, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Thursday approved the drug Elevidys (delandistrogene moxeparvovec-rokl), the first gene therapy for the treatment of children with Duchenne muscular dystrophy (DMD).The…
Learn MoreFDA Approves First Gene Therapy to Treat Duchenne Muscular Dystrophy
FRIDAY, June 23, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Thursday approved the drug Elevidys, the first gene therapy for the treatment of children with Duchenne muscular dystrophy (DMD).The groundbreaking treatment will not b…
Learn MoreFDA Approves First Gene Therapy to Treat Duchenne Muscular Dystrophy
FRIDAY, June 23, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Thursday approved the drug Elevidys, the first gene therapy for the treatment of children with Duchenne muscular dystrophy (DMD).The groundbreaking treatment will not b…
Learn MoreVamorolone Effective, Safe for Boys With Duchenne Muscular Dystrophy
THURSDAY, Sept. 1, 2022 (HealthDay News) — For boys with Duchenne muscular dystrophy (DMD), vamorolone, a structurally unique dissociative steroidal anti-inflammatory drug, is effective and safe over a 24-week period, according to a study published…
Learn More